FDA label
What is Verquvo used for?
Verquvo contains vericiguat. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “VERQUVO® is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Verquvo?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Verquvo, tablet, film coated
Indications and Usage, quoted from the label by Merck Sharp & Dohme LLC (NDA214377). Cross-references to other label sections are left out.
VERQUVO® is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.
Source: DailyMed label, set id 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d, version 13, effective January 21, 2026. NDC 0006-5028, one of 3 listings for this product.
Questions
What is Verquvo used for?
The FDA label says: “VERQUVO® is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.”
What drug class is Verquvo?
FDA lists vericiguat in the Soluble Guanylate Cyclase Stimulator established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.